Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alois Walder"'
Autor:
Alois Walder, Van Anh Nguyen, Sergej Skvortsov, Matthias Schmuth, Fiona André, Nina Frischhut
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 18:754-757
Autor:
Alois Walder, Van Anh Nguyen, Sergej Skvortsov, Nina Frischhut, Matthias Schmuth, Fiona André
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 18:754-757
Autor:
Alois Walder, Hans Maier, Guenther Stockhammer, Michael Steurer, Christian Uprimny, Thomas Berger, Franziska Di Pauli, Paul Rhomberg
Publikováno v:
Journal of Clinical Virology. 60:424-427
A 58-year old female with a four-year history of previously untreated CLL at Binet stage A complained about word finding problems, impaired vision, and gait unsteadiness. Concerning her CLL she was asymptomatic and had never required any specific tre
Publikováno v:
memo - Magazine of European Medical Oncology. 3:19-22
In the last decade, many novel immunomodulating therapies and “biologicals”, usually acting as signal transduction inhibitors, came into routine therapy in cancer. Mostly, these substances are well tolerated, and there is a typical spectrum of co
Autor:
Gabriele Gamerith, Ines Wasle, Patrizia Mondello, Werner Linkesch, Florian Kocher, Jutta Auberger, Alois Walder, Michael Mian, Thomas Melchardt, Thomas Jaeger, Michael Fiegl
Publikováno v:
Annals of hematology. 94(4)
The anthracycline doxorubicin plays a major role in the treatment of lymphoproliferative disorders. However, its use is often limited due to cardiac toxicity, which seems to be much less in the liposomal non-pegylated formulation (Myocet®). The aim
Autor:
Jiří Mayer, Richard Greil, Reinhard Stauder, Michael Mian, August Zabernigg, Michael Fiegl, Georg Hopfinger, Michael Steurer, Cathrin Skrabs, F. Schmid, Alois Lang, Alois Walder, F. Haslbaur, G. Winder, Guenther Gastl, Daniela Voskova, Yvona Brychtová
Publikováno v:
Annals of hematology. 93(2)
This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced B-cell chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (B-PLL) to definitely describe the impact of this antibody in clinica
Autor:
Stefan Schmidt, Alois Walder, Wolfgang Linkesch, Josef Thaler, Manfred Mitterer, Otto Krieger, Sonja Burgstaller, Ernst Schlögl, Günther Gastl, Hermine Agis, Andreas L. Petzer, Michael A. Fridrik, Markus Korger, Wolfgang Eisterer, Alois Lang, Ernst Wöll, Michael Pober, Peter Valent, Dominik Wolf, Tamer Sliwa
Publikováno v:
Wiener klinische Wochenschrift. 122(19-20)
The Austrian chronic myeloid leukemia (CML) registry monitors individual disease courses, treatments applied, clinical outcome, and side effects of CML patients on a nationwide basis to provide data on the "real-life" situation and to complement the